Tags : Cardiovascular Diseases

Pfizer Signs an Option and License Agreement with Voyager to

Tuba Khan October 7, 2021

Shots: Voyager to receive $30M up front, $20M as exercise fees for 2 options (exercisable within 12mos.) & ~$580M as development, regulatory & commercial milestones related to licensed products including […]readmore

Pharma

AstraZeneca Signs an Agreement with Gatehouse Bio to Identify New

Tuba Khan December 5, 2019

Shots: AstraZeneca collaborates with Gatehouse Bio to explore new targets for respiratory and CV diseases utilizing Gatehouse Bio’s AI-powered sRNAlytics platform The collaboration allows Gatehouse Bio to develop next-generation therapies […]readmore

Tags : Cardiovascular Diseases

Pfizer Signs an Option and License Agreement with Voyager to

AstraZeneca Signs an Agreement with Gatehouse Bio to Identify New

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Cardiovascular Diseases

Pfizer Signs an Option and License Agreement with Voyager to

AstraZeneca Signs an Agreement with Gatehouse Bio to Identify New

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company